SKLB-03220
SKLB-03220 is an orally bioavailable covalent inhibitor targeting the histone methyltransferase EZH2, an established oncology drug target involved in epigenetic regulation. SKLB-03220 is structurally based on the clinically approved EZH2 inhibitor tazemetostat and demonstrates the ability to abolish epigenetic H3K27me3 marks, thereby altering chromatin state and transcriptional activity. SKLB-03220 represents a potent small-molecule tool for cancer epigenetics research.
Product Specifications
CAS Number
2852050-29-2
Product Name Alternative
SKLB03220, Sklb-03220
Field of Research
Epigenetics & Chromatin
Purity
97.01% (May vary between batches)
Smiles
O=C (C=C) NC1=CC=C (C (=C1) C=2C=C (C (=O) NCC=3C (=O) NC (=CC3C) C) C (=C (C2) N (CC) C4CCOCC4) C) C
Molecular Formula
C33H40N4O4
Molecular Weight
556.71
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS6424990-01 0.1 mL
LSP1 (Leukocyte Specific Protein 1, WP34, pp52) (APC)
Sign In for Pricing
View Details MBS6424990-02 5x 0.1 mL
LSP1 (Leukocyte Specific Protein 1, WP34, pp52) (APC)
Sign In for Pricing
View Details 
M1203-03V-ML650 100 µL
Macrophage, Monocyte Chemotactic Protein-5 (MCP-5, CCL12) (MaxLight 650)
Sign In for Pricing
View Details